Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

897.00 -19.31 (-2.11%)

Official Closing Price Updated: 4:01 PM EDT, Mar 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2

...

29 30 31 32 33 34 35 36 37

...

99 100 Next >

Pfizer Clinches $10 Billion Deal To Buy Obesity Drug Maker Metsera, Outbidding Novo Nordisk In Fierce Battle For Weight-Loss Market Dominance ↗

November 08, 2025

Nvidia CEO Jensen Huang cautioned Elon Musk against underestimating the challenges of semiconductor manufacturing, saying building a chip fab like TSMC's is "extremely hard."

Via Benzinga

S&P 500: The Bull Market Is Just Getting Started

November 07, 2025

The S&P 500 has been on an impressive ascent, with market sentiment in November 2025 largely skewed towards cautious optimism. After a robust year of gains, driven significantly by the "mania around...

Via MarketMinute

Why Novo Nordisk Stock Is Sinking This Week ↗

November 07, 2025

The global drugmaker is facing some headwinds related to tough competition.

Via The Motley Fool

Topics Government World Trade

Trump Announces Deals With Eli Lilly, Novo Nordisk To Lower Obesity Drug Prices ↗

November 06, 2025

Via Stocktwits

Topics Government

Eli Lilly, Novo Nordisk Or A Dark Horse: Which Obesity-Drug Stock Are Retail Traders Most Bullish On Over Next 5 Years? ↗

November 06, 2025

Via Stocktwits

Why Nvidia (NVDA) Stock Is Falling Today

November 07, 2025

Shares of leading designer of graphics chips Nvidia (NASDAQ:NVDA) fell 4.1% in the afternoon session after the stock retreated amid renewed concerns about stretched valuations in the AI space and...

Via StockStory

Topics Artificial Intelligence

Eli Lilly's Investigational Obesity Drug Shows Up To 20% Weight Loss In Phase 2 Study, Analyst Sees It As Emerging Cornerstone In Obesity Treatment ↗

November 07, 2025

Eli Lilly's eloralintide cut body weight by up to 20% in a Phase 2 trial, showing strong efficacy and potential to advance obesity treatment.

Via Benzinga

Navigating the Shifting Tides: Experts Chart Course for 2025 Stock Market

November 07, 2025

As the calendar turns towards late 2025, leading financial experts are providing a detailed compass for investors, navigating a stock market characterized by cautious optimism, elevated valuations, and...

Via MarketMinute

Topics Artificial Intelligence Economy World Trade

FDA Fast-Tracks 6 More Drugs - Obesity And Cancer Drugs Included ↗

November 07, 2025

FDA adds six drugs to its priority voucher program as CMS and the White House unveil measures to speed reviews and lower prescription costs.

Via Benzinga

Eli Lilly’s Weight-Loss Drug Mounjaro Becomes India’s Top-Selling Medicine By Value: Report ↗

November 07, 2025

The drug has surpassed GlaxoSmithKline’s antibiotic Augmentin, according to a Reuters report on Friday, citing data from research firm Pharmarack.

Via Stocktwits

Topics Government

The Weight-Loss Drugs Craze Is Going Strong. But Stock Investors Should Know A Few Things. ↗

November 07, 2025

The feast that saw obesity-tied stocks skyrocket in 2024 is over. Investors' appetite for weight-loss drugs has waned.

Via Investor's Business Daily

Topics Government

Eli Lilly Stock Defies Trump’s GLP-1 Pricing Pressure With 6-Day Rally As Wall Street Cheers FDA Boost And New Weight-Loss Drug Data ↗

November 06, 2025

Bank of America Securities called Lilly’s GLP-1 pricing deal “probably a good tradeoff overall,” keeping a ‘Buy’ rating and $950 target.

Via Stocktwits

Topics Government World Trade

Can Hims & Hers Keep Its GLP-1 Edge After Trump Forces Lilly And Novo To Slash Prices? Wall Street Isn’t Convinced ↗

November 06, 2025

Citi calls Trump’s GLP-1 pricing deal “less bad than feared,” while Needham warns it could erode Hims’ cost advantage.

Via Stocktwits

Topics Government World Trade

Eli Lilly Crushed Novo In Obesity Drug Battle—Trump Now Forces Price Cuts ↗

November 06, 2025

Trump secures a major deal with Eli Lilly and Novo Nordisk to cut obesity drug costs as Medicare expands coverage for Zepbound and Wegovy by 2026.

Via Benzinga

Topics Government

Eli Lilly, Novo Nordisk Make Weight-Loss Drugs More Affordable Via Medicare, Medicaid, TrumpRx ↗

November 06, 2025

The Trump administration struck deals with Eli Lilly and Novo Nordisk to lower obesity drug prices and expand Medicare coverage starting in 2026.

Via Benzinga

Topics Government

Novo Nordisk Has Downgraded Its Outlook for the Fourth Time This Year. Here's What Investors Need to Know. ↗

November 06, 2025

Is the fourth time the charm for this Danish pharmaceutical giant?

Via The Motley Fool

Topics Earnings

Trump Slashes Weight-Loss Drug Prices By Up To 74% In Deal With Lilly, Novo ↗

November 06, 2025

The Trump administration announced deals Thursday with Eli Lilly and Novo Nordisk to slash the prices of their obesity drugs.

Via Investor's Business Daily

Topics Government

Navigating the Volatility: Q3 2025 Earnings Season Delivers Both Cheers and Concerns

November 06, 2025

The third-quarter 2025 earnings season, largely drawing to a close in early November, has proven to be a dynamic and often surprising period for investors. While a significant majority of S&P 500...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High

November 06, 2025

San Diego, CA – November 6, 2025 – Ligand Pharmaceuticals (NASDAQ: LGND) has recently captured the financial spotlight, with its stock hitting a remarkable 52-week high of $197.78 on November 6, 2025....

Via MarketMinute

Topics Intellectual Property

My 6 Top-Ranked Stocks to Buy Right Now in November ↗

November 06, 2025

Whether you're looking for AI stocks or dividend stocks, there is something for everyone in this list.

Via The Motley Fool

Topics Artificial Intelligence

Trump Administration's Weight-Loss Drug Deal Is Sending This Novo Nordisk Rival Surging: Momentum Score Spikes ↗

November 06, 2025

A leading pharmaceutical stock that goes head-to-head against Novo Nordisk A/S is surging amid a potential deal with the Trump administration.

Via Benzinga

Topics Government

Dow Jumps Over 200 Points: Investor Sentiment Improves, Fear & Greed Index Remains In 'Extreme Fear' Zone ↗

November 06, 2025

The CNN Fear & Greed Index eased, but remained in Extreme Fear zone on Wed. Stocks rose on solid earnings & speculation of Fed rate cut.

Via Benzinga

Topics Economy Stocks

1 Mid-Cap Stock for Long-Term Investors and 2 We Question

November 05, 2025

Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from...

Via StockStory

ANI Pharmaceuticals (ANIP) To Report Earnings Tomorrow: Here Is What To Expect

November 05, 2025

Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) will be reporting results this Friday before the bell. Here’s what to look for.

Via StockStory

Topics Artificial Intelligence

2 Reasons I'm Keeping My Eye on Eli Lilly Stock Right Now ↗

November 05, 2025

Investing in pharmaceutical companies with diversified revenue bases and strong R&D pipelines could be a lucrative strategy.

Via The Motley Fool

Microsoft Gets $135 Billion OpenAI Stake ↗

November 05, 2025

Via The Motley Fool

The Shifting Sands of Valuation: Understanding Market Cap Movers in a Dynamic Market

November 05, 2025

In the intricate tapestry of global financial markets, few metrics hold as much sway and immediate relevance as market capitalization. Representing the total dollar value of a company's outstanding...

Via MarketMinute

Topics Artificial Intelligence Bankruptcy Earnings

The Resilient Market: Investor Optimism and the Enduring Power of "Dip-Buying" in November 2025

November 05, 2025

As November 2025 unfolds, the financial markets are characterized by a palpable sense of cautious optimism, a sentiment largely underpinned by the continued prevalence and success of "dip-buying"...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

Tech Titans and Pharma Powerhouses Drive Market Volatility: AMD, Palantir, Micron, and Eli Lilly in Focus

November 05, 2025

As of November 5, 2025, the financial markets experienced a day of notable activity, with several key players across the technology and pharmaceutical sectors capturing investor attention. Advanced...

Via MarketMinute

Topics Artificial Intelligence Economy

Obesity Drugmakers Face Shifting Tides: Novo Nordisk Plunges While Eli Lilly Soars

November 05, 2025

The burgeoning market for obesity and diabetes treatments, particularly GLP-1 receptor agonists, is witnessing a dramatic divergence in fortunes among its leading players. As of November 5, 2025, Novo...

Via MarketMinute

Topics Economy

< Previous 1 2

...

29 30 31 32 33 34 35 36 37

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.